Noninvasive tests to assess liver stiffness in patients with chronic hepatitis b: apri, fib-4, and fib-5 scores

Basit Öğe Kaydı
dc.authorid0000-0001-7792-8438
dc.contributor.authorYakut, Aysun
dc.contributor.authorAladağ, Murat
dc.date.accessioned2024-08-27T09:14:36Z
dc.date.available2024-08-27T09:14:36Z
dc.date.issued2024
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractBackground. Invasive percutaneous liver parenchymal biopsy is the best test used to evaluate liver stiffness and fibrosis in the follow-up and treatment of chronic hepatitis B (CHB) patients. In this study, we aimed to indirectly evaluate the severity of liver parenchymal fibrosis with tests used in the laboratory. Methods. This retrospective study was conducted with 201 patients diagnosed with CHB who underwent liver biopsy between 2021 and 2022. Preprocedural examination information, laboratory tests, and histopathological data of the patients were taken from the hospital database and examined. "Aspartate aminotransferase (AST)-platelet ratio index"(APRI), "4 factor-based fibrosis index"(FIB-4) score, and "5 factor-based fibrosis index"(FIB-5) score were calculated and compared with liver histopathological features. Results. Of the 201 CHB patients, 76 were females and 125 were males. The average age of the patients was 38.05 ± 12.63 years. A weak, statistically significant correlation was observed between FIB-4 and APRI scores. The patients' significant fibrosis scores were 31.3% and 33.8%, respectively (r = 0.313; r = 0.338; p=0.001; p<0.01). The very weak negative correlation of 17.4% between the patients' FIB-5 score and fibrosis score was statistically significant (r = -0.174; p=0.014; p<0.05). Conclusions. According to the data we obtained in our study, while the APRI score and FIB-4 score can be used safely, more comprehensive studies are needed for the reliability of the FIB-5 score.
dc.identifier.citationYakut, A. ve Aladağ, M. (2024). Noninvasive tests to assess liver stiffness in patients with chronic hepatitis b: apri, fib-4, and fib-5 scores. International Journal of Clinical Practice, 2024. http://dx.doi.org/10.1155/2024/5540648
dc.identifier.doi10.1155/2024/5540648
dc.identifier.issn1368-5031
dc.identifier.issn1742-1241
dc.identifier.scopus2-s2.0-85199391362
dc.identifier.scopusqualityQ2
dc.identifier.urihttp://dx.doi.org/10.1155/2024/5540648
dc.identifier.urihttps://hdl.handle.net/20.500.12511/12778
dc.identifier.volume2024
dc.identifier.wos001273360700001en_US
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.institutionauthorYakut, Aysun
dc.language.isoen
dc.relation.ispartofInternational Journal of Clinical Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAlanine Aminotransferase
dc.subjectAlkaline Phosphatase
dc.subjectAspartate Aminotransferase
dc.subject4 Factor Based Fibrosis Index
dc.subject5 Factor Based Fbrosis Index
dc.subjectChronic Hepatitis B
dc.titleNoninvasive tests to assess liver stiffness in patients with chronic hepatitis b: apri, fib-4, and fib-5 scores
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Yakut-Aysun-2024.pdf
Boyut:
421.26 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu